-
Je něco špatně v tomto záznamu ?
Re-introducing whole blood for transfusion: considerations for blood providers
TA. Hervig, HA. Doughty, RA. Cardigan, TO. Apelseth, JR. Hess, F. Noorman, M. Bohoněk, MH. Yazer, J. Lu, S. Wendel, RL. Sparrow, Biomedical Excellence for Safer Transfusion Collaborative
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, přehledy
PubMed
32996604
DOI
10.1111/vox.12998
Knihovny.cz E-zdroje
- MeSH
- krevní transfuze * MeSH
- lidé MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Whole blood is the original blood preparation but disappeared from the blood bank inventories in the 1980s following the advent of component therapy. In the early 2000s, both military and civilian practice called for changes in the transfusion support for massive haemorrhage. The 'clear fluid' policy was abandoned and replaced by early balanced transfusion of platelets, plasma and red cells. Whole blood is an attractive alternative to multi-component therapy, which offers reduced hemodilution, lower donor exposure and simplified logistics. However, the potential for wider re-introduction of whole blood requires re-evaluation of haemolysins, storage conditions and shelf-life, the need for leucocyte depletion/ pathogen reduction and inventory management for blood providers. This review addresses these questions and calls for research to define the optimal whole blood product and the indications for its use.
Blood Bank Haugesund hospital Haugesund Norway
Blood Bank Hospital Sirio Libanes São Paulo Brazil
Component Development NHS Blood and Transplant Cambridge UK
Department of Immunology and Transfusion Medicine Haukeland University Hospital Bergen Norway
Department of Pathology University of Pittsburgh Pittsburgh PA USA
Epidemiology and Preventive Medicine Monash University Melbourne Vic Australia
Hematology Biochemistry and Blood Transfusion Central Military Hospital Prague Prague Czech Republic
Laboratory Medicine University of Washington Seattle WA USA
Medical NHS Blood and Transplant Birmingham UK
Quality Research and Development Military Blood Bank Leiden Netherlands
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21019391
- 003
- CZ-PrNML
- 005
- 20231221120247.0
- 007
- ta
- 008
- 210728s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/vox.12998 $2 doi
- 035 __
- $a (PubMed)32996604
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Hervig, Tor A $u Blood Bank, Haugesund hospital, Haugesund, Norway
- 245 10
- $a Re-introducing whole blood for transfusion: considerations for blood providers / $c TA. Hervig, HA. Doughty, RA. Cardigan, TO. Apelseth, JR. Hess, F. Noorman, M. Bohoněk, MH. Yazer, J. Lu, S. Wendel, RL. Sparrow, Biomedical Excellence for Safer Transfusion Collaborative
- 520 9_
- $a Whole blood is the original blood preparation but disappeared from the blood bank inventories in the 1980s following the advent of component therapy. In the early 2000s, both military and civilian practice called for changes in the transfusion support for massive haemorrhage. The 'clear fluid' policy was abandoned and replaced by early balanced transfusion of platelets, plasma and red cells. Whole blood is an attractive alternative to multi-component therapy, which offers reduced hemodilution, lower donor exposure and simplified logistics. However, the potential for wider re-introduction of whole blood requires re-evaluation of haemolysins, storage conditions and shelf-life, the need for leucocyte depletion/ pathogen reduction and inventory management for blood providers. This review addresses these questions and calls for research to define the optimal whole blood product and the indications for its use.
- 650 12
- $a krevní transfuze $7 D001803
- 650 _2
- $a lidé $7 D006801
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Doughty, Heidi A $u Medical, NHS Blood and Transplant, Birmingham, UK
- 700 1_
- $a Cardigan, Rebecca A $u Component Development, NHS Blood & Transplant, Cambridge, UK
- 700 1_
- $a Apelseth, Torunn O $u Department of Immunology and Transfusion Medicine, Haukeland University Hospital, Bergen, Norway
- 700 1_
- $a Hess, John R. $u Laboratory Medicine, University of Washington, Seattle, WA, USA $7 xx0311953
- 700 1_
- $a Noorman, Femke $u Quality, Research and Development, Military Blood Bank, Leiden, Netherlands
- 700 1_
- $a Bohoněk, Miloš $u Hematology, Biochemistry and Blood Transfusion, Central Military Hospital Prague, Prague, Czech Republic
- 700 1_
- $a Yazer, Mark H $u Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA
- 700 1_
- $a Lu, Jia $u Defence Medical & Environmental Research Institute, DSO National Laboratories (Kent Ridge), Singapore City, Singapore
- 700 1_
- $a Wendel, Silvano $u Blood Bank, Hospital Sirio Libanes, São Paulo, Brazil
- 700 1_
- $a Sparrow, Rosemary L $u Epidemiology and Preventive Medicine, Monash University, Melbourne, Vic, Australia
- 710 2_
- $a Biomedical Excellence for Safer Transfusion Collaborative
- 773 0_
- $w MED00010756 $t Vox sanguinis $x 1423-0410 $g Roč. 116, č. 2 (2021), s. 167-174
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32996604 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20231221120242 $b ABA008
- 999 __
- $a ok $b bmc $g 1690255 $s 1139837
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 116 $c 2 $d 167-174 $e 20200930 $i 1423-0410 $m Vox sanguinis $n Vox Sang $x MED00010756
- LZP __
- $a Pubmed-20210728